Radiotherapy dosimetry and secondary radiation-induced cancer risk for early-stage nasal NK/T-cell lymphoma treated with the Halcyon 3.0 medical linear accelerator(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2026年第6期
- Page:
- 710-715
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Radiotherapy dosimetry and secondary radiation-induced cancer risk for early-stage nasal NK/T-cell lymphoma treated with the Halcyon 3.0 medical linear accelerator
- Author(s):
- XIAO Peng1; XU Tingting2; SUN Fu3; TU Honglei1; TIAN Xiumei1; LIU Xianfeng1
- 1. Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China 2. Department of Oncology and Hematology, Fengdu General Hospital, Chongqing 408200, China 3.Department of Oncology, the Peoples Hospital of Yubei District of Chongqing City, Chongqing 401102, China
- Keywords:
- associated with increased parotid gland doses and elevated secondary cancer risks in distant OAR.
Keywords: nasal NK/T-cell lymphoma intensity-modulated radiotherapy radiotherapy dosimetry secondary cancer risk
- PACS:
- R318；R811.1
- DOI:
- DOI:10.3969/j.issn.1005-202X.2026.06.002
- Abstract:
- Abstract: Objective To evaluate the dosimetric characteristics and secondary radiation-induced cancer risk in patients with early-stage nasal NK/T-cell lymphoma receiving intensity-modulated radiotherapy (IMRT) delivered on the Halcyon 3.0 medical linear accelerator. Methods A retrospective study was conducted on 22 patients with early-stage nasal NK/T-cell lymphoma. For each patient, fixed-field IMRT plans were created on both Varian Edge and Halcyon 3.0 platforms, denoted IMRT (Edge) and IMRT (Halcyon), respectively. Differences in target coverage and organ-at-risk (OAR) doses were evaluated. An excess absolute risk (EAR) model was applied to quantify and compare secondary cancer risks for the oropharynx, thyroid, and bilateral salivary glands. Results Compared with IMRT (Edge), IMRT (Halcyon) demonstrated superior target dose homogeneity (reduced by 8.51%, P=0.018), though with slightly inferior conformity (reduced by 1.70%, P=0.011). Regarding OAR sparing, IMRT (Halcyon) significantly reduced doses delivered to the optic chiasm, optic nerves, ocular globes, lenses, spinal cord, and brainstem, with reductions ranging from 5.22% to 33.42% (P<0.01). However, it also led to a significant increase in the mean dose to the bilateral parotid glands, with increases of 32.71% in the left parotid and 36.13% in the right parotid (P<0.001). Notably, IMRT (Halcyon) significantly elevated secondary cancer risks across all evaluated organs, with EAR values rising by 17.47% for the oropharynx, 53.42% for the thyroid, 51.75% for the left salivary gland, and 55.23% for the right salivary gland (P<0.001). Conclusion The Halcyon 3.0 platform provides superior target dose homogeneity and better protection for most OAR in radiotherapy for early-stage nasal NK/T-cell lymphoma. However, it is
Last Update: 2026-06-26